Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
Artificial intelligence technology has an established home in drug design for many developers. Now, researchers are seeing AI technology as a potential tool in driving therapeutic choices in the treatment of ovarian cancer.
AstraZeneca filed a Worker Readjustment and Retraining Notification Act (WARN) notice with the State of Colorado, indicating plans to lay off 210 people in Boulder and Longmont.
UroGen Pharma announced positive top-line results from the New York based-company’s Phase III OLYMPUS clinical trial that evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer.
Eli Lilly and Company and Loxo Oncology Inc. announced a definitive agreement for Lilly to acquire Loxo for $235.00 per share in cash, or approximately $8.0 billion.
Selecta Biosciences announced restructuring efforts that include reducing the Watertown, Mass.-based company’s workforce by 36 percent.
Privately held Tizona Therapeutics snagged $105 million in upfront cash as the company’s cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie.
Germany-based BioNTech extended a three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.
Personal Genome Diagnostics Collaborates with Merck on Global Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).
Personal Genome Diagnostics and KingMed Enter Strategic Partnership to make Comprehensive Genomic Tissue Panel with TMB available in China and Hong Kong
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and KingMed Diagnostics, a laboratory services leader in China, announced that they have entered into a strategic partnership for the PGDx elioTM tissue complete assay.